<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">IJCM</journal-id><journal-title-group><journal-title>International Journal of Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2158-284X</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.4236/ijcm.2015.612117</article-id><article-id pub-id-type="publisher-id">IJCM-61778</article-id><article-categories><subj-group subj-group-type="heading"><subject>Articles</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine&amp;Healthcare</subject></subj-group></article-categories><title-group><article-title>
 
 
  Familial Lupus and Clinical Characteristics in Saudi Arabia
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>amal</surname><given-names>Abdullah Albishri</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Samar</surname><given-names>Saad Alshehri</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Alwalaa</surname><given-names>Mohammed Altowairqi</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>Reem</surname><given-names>Magboul Aljuaid</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>Taif University, Taif, Saudi Arabia</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>jbeshri@gmail.com(AAA)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>08</day><month>12</month><year>2015</year></pub-date><volume>06</volume><issue>12</issue><fpage>899</fpage><lpage>905</lpage><history><date date-type="received"><day>13</day>	<month>November</month>	<year>2015</year></date><date date-type="rev-recd"><day>accepted</day>	<month>5</month>	<year>December</year>	</date><date date-type="accepted"><day>8</day>	<month>December</month>	<year>2015</year></date></history><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  Background: It has been proven that a family history of systemic lupus erythematosus (SLE) is a risk factor for the development of the disease, and the risk increases with increasing number of relatives affected. In Saudi Arabia, high consanguinity rate leads to higher incidence of familial form than in other countries. We compare the percentage of familial versus sporadic SLE among Saudi patients. The second aim of the present study is to compare clinical characteristics between the two forms of the disease. Methods: This cross-sectional study includes 47 female patients whom are selected and investigated through three phases. We have added additional two categories of relatives, based on unconventional definition. We have examined and compared demographic characteristics of the patients with familial and sporadic SLE. We have also compared the percentage of familial vs. sporadic lupus and clinical characteristics of the two forms. Results: All the patients are females, aged between 18 and 43 years. The highest percentage of patients resides in the central region of Saudi Arabia (34%). The origin of the big family or tribe also most commonly occurs in the central region (34%). Data analysis results in 27.7% of patients with familial form of SLE. Sporadic form is found in 72.3% of patients. Consanguinity between patients’ parents is noticed in both familial form (61.5%) and sporadic form (58.8%). Clinical manifestations are similar between patients with familial and sporadic form. Conclusion: Our results show a high percentage of familial lupus among Saudi patients. More research is required in order to estimate the inheritance pattern of familial SLE and involvement of genetic and environmental factors.
 
</p></abstract><kwd-group><kwd>SLE</kwd><kwd> Lupus</kwd><kwd> Familial</kwd><kwd> Saudi Arabia</kwd><kwd> Genetics</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>1. Introduction</title><p>Investigation of epidemiological features of systemic lupus erythematosus (SLE) has always been a great challenge. Giving that SLE has a broad spectrum of clinical modalities and variable immunological profiles, the definition of the disease, classification criteria, as well as epidemiological study approaches change frequently over time [<xref ref-type="bibr" rid="scirp.61778-ref1">1</xref>] .</p><p>Addressing the prevalence of SLE in the population of Saudi Arabia is a controversial topic, mainly due to lack of scientific evidence. A study conducted in Al-Qaseem region of Saudi Arabia showed prevalence of SLE of 19.28 per 100,000 people [<xref ref-type="bibr" rid="scirp.61778-ref2">2</xref>] . There were studies showing both higher [<xref ref-type="bibr" rid="scirp.61778-ref3">3</xref>] and lower [<xref ref-type="bibr" rid="scirp.61778-ref4">4</xref>] prevalence of SLE in Saudi Arabia compared to developed countries.</p><p>Epidemiological data have shown substantial influence of genetic factors on the development of SLE [<xref ref-type="bibr" rid="scirp.61778-ref5">5</xref>] . It has been proven that family history of SLE is a risk factor for the development of the disease, and the risk increases with increasing number of relatives affected [<xref ref-type="bibr" rid="scirp.61778-ref6">6</xref>] . The results from studies conducted in different countries show that 4% - 11% of SLE patients have at least one first-degree relative affected [<xref ref-type="bibr" rid="scirp.61778-ref7">7</xref>] . Majority of SLE patients still have sporadic form of the disease.</p><p>In Saudi Arabia, due to specific demographic profiles and cultural characteristics, genetic factors may have a much higher influence, resulting in higher incidence of familial form of SLE than in other countries. During the history, the majority of the population is organized in tribal manner based on a particular bloodline. Up until the second half of the 20th century, marriage between different classes was not normally considered, and endogamy was very pronounced [<xref ref-type="bibr" rid="scirp.61778-ref8">8</xref>] . This can indicate the cause of high incidence of consanguinity among the Saudi Arabian population, which is confirmed in one study conducted among 3212 Saudi families [<xref ref-type="bibr" rid="scirp.61778-ref9">9</xref>] . Based on the study results, they classify Saudi Arabia among countries with high rate of consanguinity. Therefore, Saudi Arabia has a high prevalence of autosomal and X linked recessive disorders.</p><p>As the genetics of SLE is still poorly investigated, the comparison of prevalence of sporadic and familial form of the disease in the population of specifically Saudi Arabia can open a new era of understanding of the genetic background in the development of the disease.</p><p>In this study, we compare the percentage of familial versus sporadic lupus among Saudi patients, and interpret the results considering specific demographic characteristics of the Saudi population. The second aim of the pre- sent study is to compare the clinical characteristics between the two forms of the disease.</p></sec><sec id="s2"><title>2. Methods</title><p>The patients were first contacted via a group called “The Red Butterfly” created by one patient with SLE, on the WhatsApp social platform. The group was initiated in May 2014 and it has attracted a significant number of Arabic female patients via social networks, such as Facebook, Twitter, and Instagram. The group was founded for social and educational purposes. We were invited to become members of the group and we proposed other members to participate in this cross-sectional study in February 2015.</p><p>Each member of the group was communicated through three phases: WhatsApp phase, phone communication phase, and email phase. WhatsApp platform was used to initially contact each member of the group in order to get their agreement to participate in the phone communication phase. Phone communication phase was arranged using special format which consisted of: 1) the initial consent section which was done over the phone and documented; 2) general medical history; 3) extensive family history focused on occurrence of lupus among their relatives. During the email phase, each patient was asked to provide their medical report which confirms the diagnosis of SLE based on 1982 American College of Rheumatology (ACR) criteria. They all had informed consent to participate in the study. Both medical report and informed consent were sent in the form of scanned documents.</p><p>Of 71 patients, 14 were excluded for not being of Saudi nationality, 8 did not provide medical reports, and two did not answer phone calls, resulting in total of 47 patients who were included in the study.</p><p>In order to define the terms: first, second, and third degree relative, we used the definition of National Genetics and Genomics (NHS) [<xref ref-type="bibr" rid="scirp.61778-ref10">10</xref>] . First degree relative is considered a parent, sibling, or a child. A first degree relative shares approximately half of their genes with the person. A second degree relative is an uncle, aunt, nephew, niece, grandparent, grandchild or half-sibling. A second degree relative shares about one quarter of their genes with the person. A third degree relative is a first cousin, great-grandparent or great-grandchild. A third degree relative shares about one eighth of their genes with the person. Familial lupus was diagnosed with at least 2 relatives (1st, 2nd, or 3rd degree) with SLE.</p><p>We added an additional two categories of relatives, they don’t meet the definition of National Genetics and Genomics (NHS) but they stem from the same tribe. For these family members, the number of genes they share with the patient is uncertain. A fourth degree relative does not meet the above criteria for first, second, and third degree relatives, but claim that they descend from the same great-great grand-father (Fakith or the small family). Fifth grade family members claim that they descend from one of the two eponyms Arab ancestor (Qabila or the big family) [<xref ref-type="bibr" rid="scirp.61778-ref8">8</xref>] .</p><p>We have examined demographic characteristics of the patients and the prevalence of familial lupus among first, second, and third degree relatives. We have also compared the percentage of familial versus sporadic form of the disease. Differences in clinical characteristics in familial and sporadic form of the disease were also assessed.</p></sec><sec id="s3"><title>3. Statistical Analysis</title><p>Collected data were analyzed with the statistical software program IBM SPSS Statistics V.19. A descriptive analysis was carried out by the calculation of mean, median, SD, minimum and maximum, where applicable. We performed two-tailed student t test to compare familial versus sporadic form.</p></sec><sec id="s4"><title>4. Results</title><p>A total of 47 patients participated in this study. All the patients were female, aged between 18 and 43 years (<xref ref-type="table" rid="table1">Table 1</xref>). The highest percentage of patients resided in the central region of Saudi Arabia 16 (34%) at the time of the study, while the lowest number of patients were located in the northern region 3 (6.4%) (<xref ref-type="table" rid="table1">Table 1</xref>). The origin of the big family or tribe was also most common in the central region of Saudi Arabia 16 (34%), while the distribution of patients in other regions was similar (<xref ref-type="table" rid="table1">Table 1</xref>).</p><p>The data analysis resulted in 13 (27.7%) patients with at least one 1st, 2nd, or 3rd degree relative diagnosed with SLE which we assigned to Category A (familial form) (<xref ref-type="table" rid="table2">Table 2</xref>). Sporadic form of SLE was found in 34 (72.3%) patients who had no 1st, 2nd, or 3rd degree relatives affected with SLE, assigned to Category B (<xref ref-type="table" rid="table2">Table 2</xref>). There were 19 (40.4%) patients with at least one 1st, 2nd, 3rd, 4th, or 5th degree relative diagnosed with SLE</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Demographic characteristics of the participants</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Parameters</th><th align="center" valign="middle" >Values</th></tr></thead><tr><td align="center" valign="middle" >Total No.</td><td align="center" valign="middle" >47</td></tr><tr><td align="center" valign="middle" >Age ( mean &#177; SD) years</td><td align="center" valign="middle" >18 - 43 (28.2 &#177; 6.03)</td></tr><tr><td align="center" valign="middle" >Female sex No. (%)</td><td align="center" valign="middle" >47 (100)</td></tr><tr><td align="center" valign="middle" >Marital status No. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >Married</td><td align="center" valign="middle" >18 (38.3)</td></tr><tr><td align="center" valign="middle" >Single</td><td align="center" valign="middle" >29 (61.7)</td></tr><tr><td align="center" valign="middle" >Region of origin No. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >West</td><td align="center" valign="middle" >7 (14.9)</td></tr><tr><td align="center" valign="middle" >North</td><td align="center" valign="middle" >7 (14.9)</td></tr><tr><td align="center" valign="middle" >South</td><td align="center" valign="middle" >10 (21.3)</td></tr><tr><td align="center" valign="middle" >East</td><td align="center" valign="middle" >7 (14.9)</td></tr><tr><td align="center" valign="middle" >Middle</td><td align="center" valign="middle" >16 (34)</td></tr><tr><td align="center" valign="middle" >Residence No. (%)</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >West</td><td align="center" valign="middle" >13 (27.7)</td></tr><tr><td align="center" valign="middle" >North</td><td align="center" valign="middle" >3 (6.4)</td></tr><tr><td align="center" valign="middle" >South</td><td align="center" valign="middle" >5 (10.6)</td></tr><tr><td align="center" valign="middle" >East</td><td align="center" valign="middle" >10 (21.3)</td></tr><tr><td align="center" valign="middle" >Middle</td><td align="center" valign="middle" >16 (34)</td></tr></tbody></table></table-wrap><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Distribution of patients with SLE by presence of the disease among family members</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >Patient (Serial No.)</th><th align="center" valign="middle" >Female: male ratio (including the patient)</th><th align="center" valign="middle" >Total number of affected relatives</th><th align="center" valign="middle" >First degree relatives (No.)</th><th align="center" valign="middle" >Second degree relatives (No.)</th><th align="center" valign="middle" >Third degree relatives (No.)</th><th align="center" valign="middle" >Fourth degree relatives (small family or Fakith)</th><th align="center" valign="middle" >Fifth degree relatives (big family or Qabila)</th></tr></thead><tr><td align="center" valign="middle"  colspan="8"  >Familial Lupus (Category A) Total = 13 (27.7)</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >2:1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2:1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >3:0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >3:0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >7</td><td align="center" valign="middle" >6:1</td><td align="center" valign="middle" >6</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >5</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >8</td><td align="center" valign="middle" >3:0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >9</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >10</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >11</td><td align="center" valign="middle" >2:1</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td></tr><tr><td align="center" valign="middle" >12</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >13</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="8"  >Sporadic Lupus ( Category B1 &amp; B2) Total (%) = 34 (72.3)</td></tr><tr><td align="center" valign="middle"  colspan="8"  >Participants with distant affected relative(s) who do not meet the familial lupus definition Category (B1) Total (%) = 6 (12.7)</td></tr><tr><td align="center" valign="middle" >1</td><td align="center" valign="middle" >3:0</td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >2</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >2</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >3</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >4</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >5</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle" >6</td><td align="center" valign="middle" >2:0</td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >1</td><td align="center" valign="middle" ></td></tr><tr><td align="center" valign="middle"  colspan="8"  >Participants with no affected relatives (Category B2), Total (%)= 28 (59.6)</td></tr></tbody></table></table-wrap><p>categorized as B1 (<xref ref-type="table" rid="table2">Table 2</xref>). The number of patients with no relatives affected with SLE (1st, 2nd, 3rd, 4th, or 5th degree) was 28 (59.6%) and they were assigned to Category B2 (<xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Age of patients was similar in the familial and sporadic groups (28.3 &#177; 6.49 vs. 28.1 &#177; 5.95; <xref ref-type="table" rid="table3">Table 3</xref>). A higher consanguinity level between parents of the patients (1st, 2nd, 3rd, 4th, or 5th degree relatives) was noticed in both familial form (61.5%), and sporadic form (58.8%) of the disease (<xref ref-type="table" rid="table3">Table 3</xref>). In a familial group, patients’ parents were 3rd degree relatives in 46.2% of cases, while the percentage was lower in sporadic group (41.2%; <xref ref-type="table" rid="table3">Table 3</xref>). Analysis of distribution of patients with sporadic form by regions of residence resulted in the highest percentage of patients from the central region of Saudi Arabia (35.3%), followed by the western region (32.4%) (<xref ref-type="fig" rid="fig1">Figure 1</xref>). An equally high percentage of patients with familial form had residence in the east and central region (30.8%; <xref ref-type="fig" rid="fig1">Figure 1</xref>). Patients with the sporadic form had their origins in the tribes predominantly from the central region (35.3%), while patients with familial form originated mostly from Eastern and central region (30.8%) (<xref ref-type="fig" rid="fig2">Figure 2</xref>).</p><p>Systemic involvement of SLE included several different manifestations: musculoskeletal (arthritis and arthralgia), constitutional (fever, weight loss, and fatigue), skin (alopecia, photosensitivity, Raynaud’s, urticaria, vasculitis, and purpura), discoid, gastrointestinal (nausea, vomiting, and abdominal pain), renal (proteinuria, haematuria, nephrotic syndrome), haematological (anemia, thrombocytopenia, and leucopenia), cardiac (pericarditis, endocarditis, and myocarditis), CNS (seizures, psychosis, peripheral and cranial neuropathy), and pulmonary (pleurisy, parenchymal disease, pulmonary hypertension) (<xref ref-type="table" rid="table4">Table 4</xref>). The most common clinical manifestations</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Age, marital status, and consanguinity between parents of patients with familial and sporadic form of SLE</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Parameters</th><th align="center" valign="middle"  colspan="2"  >Values</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >Familial</td><td align="center" valign="middle" >Sporadic</td></tr><tr><td align="center" valign="middle" >Age (mean &#177; SD) years</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >28.3 &#177; 6.49</td><td align="center" valign="middle" >28.1 &#177; 5.95</td></tr><tr><td align="center" valign="middle" >Marital status No. (%)</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >4.0 (30.8)</td><td align="center" valign="middle" >14.0 (41.2)</td></tr><tr><td align="center" valign="middle"  rowspan="7"  >Consanguinity between parents No. (%)</td><td align="center" valign="middle" >1st degree</td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >2nd degree</td><td align="center" valign="middle" >0 (0)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >3rd degree</td><td align="center" valign="middle" >6 (46.2)</td><td align="center" valign="middle" >14 (41.2)</td></tr><tr><td align="center" valign="middle" >4th degree</td><td align="center" valign="middle" >1 (7.7)</td><td align="center" valign="middle" >2 (5.9)</td></tr><tr><td align="center" valign="middle" >5th degree</td><td align="center" valign="middle" >1 (7.7)</td><td align="center" valign="middle" >4 (11.8)</td></tr><tr><td align="center" valign="middle" >Any degree</td><td align="center" valign="middle" >8 (61.5)</td><td align="center" valign="middle" >20 (58.8)</td></tr><tr><td align="center" valign="middle" >No consanguinity</td><td align="center" valign="middle" >5 (38.5)</td><td align="center" valign="middle" >14 (41.2)</td></tr></tbody></table></table-wrap><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Clinical characteristics of patients with sporadic and familial form of SLE</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  colspan="2"  >Parameters</th><th align="center" valign="middle"  colspan="2"  >Values</th></tr></thead><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >Sporadic</td><td align="center" valign="middle" >Familial</td></tr><tr><td align="center" valign="middle" >Systemic involvement No. (%)</td><td align="center" valign="middle" >Musculoskeletal<sup>*</sup></td><td align="center" valign="middle" >27 (79.41)</td><td align="center" valign="middle" >12 (92.31)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Constitutional<sup>†</sup></td><td align="center" valign="middle" >4 (11.76)</td><td align="center" valign="middle" >3 (23.08)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Skin<sup>‡</sup></td><td align="center" valign="middle" >25 (73.53)</td><td align="center" valign="middle" >9 (69.23)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Discoid</td><td align="center" valign="middle" >8 (23.53)</td><td align="center" valign="middle" >2 (15.38)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Gastrointestinal<sup>&#167;</sup></td><td align="center" valign="middle" >3 (8.82)</td><td align="center" valign="middle" >1 (7.69)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Renal<sup>**</sup></td><td align="center" valign="middle" >19 (55.88)</td><td align="center" valign="middle" >8 (61.54)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Haematological<sup>††</sup></td><td align="center" valign="middle" >22 (64.71)</td><td align="center" valign="middle" >9 (69.23)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Cardiac<sup>‡‡</sup></td><td align="center" valign="middle" >1 (2.94)</td><td align="center" valign="middle" >1 (7.69)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >CNS<sup>&#167;&#167;</sup></td><td align="center" valign="middle" >10 (29.41)</td><td align="center" valign="middle" >7 (53.85)</td></tr><tr><td align="center" valign="middle" ></td><td align="center" valign="middle" >Pulmonary<sup>***</sup></td><td align="center" valign="middle" >3 (8.82)</td><td align="center" valign="middle" >0 (0)</td></tr><tr><td align="center" valign="middle" >Onset age (mean &#177; SD) years</td><td align="center" valign="middle" ></td><td align="center" valign="middle" >21.6 &#177; 5</td><td align="center" valign="middle" >22.1 &#177; 5.95</td></tr><tr><td align="center" valign="middle"  colspan="2"  >Number of ward admissions (mean &#177; SD)<sup>†††</sup></td><td align="center" valign="middle" >1.3 &#177; 4.07</td><td align="center" valign="middle" >0.5 &#177; 0.44</td></tr><tr><td align="center" valign="middle" >Number of ICU admissions (mean &#177; SD)<sup>‡‡‡</sup></td><td align="center" valign="middle" ></td><td align="center" valign="middle" >0.1 &#177; 0.35</td><td align="center" valign="middle" >0 &#177; 0.02</td></tr></tbody></table></table-wrap><p><sup>*</sup>Arthritis and arthralgia; <sup>†</sup>fever, weight loss, and fatigue; <sup>‡</sup>alopecia, photosensitivity; Raynaud’s, urticaria, vasculitis, and purpura; <sup>&#167;</sup>nausea, vomiting, and abdominal pain; <sup>**</sup>proteinuria, haematuria, nephrotic syndrome; <sup>††</sup>anemia, thrombocytopenia, leucopenia; <sup>‡‡</sup>pericarditis, endocarditis, myocarditis; <sup>&#167;&#167;</sup>seizures, psychosis, peripheral and cranial neuropathy; <sup>***</sup>pleurisy, parenchymal disease, pulmonary hypertension.</p><fig id="fig1"  position="float"><label><xref ref-type="fig" rid="fig1">Figure 1</xref></label><caption><title> Distribution of familial and sporadic form of SLE by patients’ residence</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/2-2101238x7.png"/></fig><fig id="fig2"  position="float"><label><xref ref-type="fig" rid="fig2">Figure 2</xref></label><caption><title> Distribution of familial and sporadic form of SLE by patients’ origin</title></caption><graphic mimetype="image"   position="float"  xlink:type="simple"  xlink:href="http://html.scirp.org/file/2-2101238x8.png"/></fig><p>in patients with both sporadic and familial form were musculoskeletal (S: 79.41%, F: 92.31%), skin-related (S: 73.53%, F: 69.23%), and hematological (S: 64.71%, F: 69.23%) (<xref ref-type="table" rid="table4">Table 4</xref>). Musculoskeletal, constitutional, renal, hematological, cardiac, and CNS-related manifestations were more common in familial than in sporadic groups, and there was no pulmonary manifestation in familial group (<xref ref-type="table" rid="table4">Table 4</xref>). No statistically significant difference was found in clinical manifestations between patients with familial and sporadic forms.</p><p>The onset age ranged from 10 to 30 years in the sporadic group (21.6 &#177; 5), and from 14 to 33 years in familial group (22.1 &#177; 5.95) (<xref ref-type="table" rid="table4">Table 4</xref>). Average number of ward admissions was higher in the sporadic group (1.3 &#177; 4.07), compared to the familial group (0.5 &#177; 0.44) (<xref ref-type="table" rid="table4">Table 4</xref>). Also, the average number of ICU admissions was higher in the sporadic group (0.1 &#177; 0.35) than in the familial group (0 &#177; 0.02) (<xref ref-type="table" rid="table4">Table 4</xref>).</p></sec><sec id="s5"><title>5. Discussion</title><p>Research showed that the highest percentage of patients both originated and were resident in the Central region of Saudi Arabia (<xref ref-type="table" rid="table1">Table 1</xref>). These results remained nearly the same when we compared percentages in familial and sporadic group, with the exceptions regarding residence in the Western region and origin of the patients in the Eastern region. Patients (<xref ref-type="fig" rid="fig1">Figure 1</xref> and <xref ref-type="fig" rid="fig2">Figure 2</xref>). To our knowledge, this is the first study showing regional distribution of sporadic and familial lupus in Saudi patients. Differences in regional distribution of familial form of SLE can stem from different consanguinity rates between the regions. Prevalence of consanguinity by region have been investigated by other studies, and the current evidences show the highest overall consanguinity rate of 67.2% in Medina region, while the lowest consanguinity rate of 42.1% was noted in Al-Baha region [<xref ref-type="bibr" rid="scirp.61778-ref11">11</xref>] .</p><p>Since familial SLE is suggested to have an autosomal recessive pattern of inheritance [<xref ref-type="bibr" rid="scirp.61778-ref12">12</xref>] , consanguinity is considered a significant risk factor for its development [<xref ref-type="bibr" rid="scirp.61778-ref13">13</xref>] . In our study, overall consanguinity rate between patients’ parents was high in both familial and sporadic group (61.5% vs. 58.8%; <xref ref-type="table" rid="table3">Table 3</xref>). These results could suggest that consanguinity may be the cause of higher prevalence of SLE in Saudi Arabia compared with developed countries [<xref ref-type="bibr" rid="scirp.61778-ref3">3</xref>] . In one study from Kuwaiti population [<xref ref-type="bibr" rid="scirp.61778-ref14">14</xref>] , which is also considered highly consanguineous, the prevalence of familial SLE was 27.4%, which is almost identical to our results (27.7%; <xref ref-type="table" rid="table2">Table 2</xref>).</p><p>Although we used the same criteria for familial SLE as other studies, we have also extended the research to distant relatives, and found that 6 patients (12.7%) had at least one 4th and/or 5th degree relative affected with SLE (<xref ref-type="table" rid="table2">Table 2</xref>). In relation to this, we found higher percentage of patients’ parents being 4th degree relatives in familial group than in sporadic group (7.7% vs. 5.9%; <xref ref-type="table" rid="table3">Table 3</xref>), but the results went in the opposite direction for 5th degree relatives (7.7% vs. 11.8%; <xref ref-type="table" rid="table3">Table 3</xref>). This could mean that the risk of SLE can still be pronounced in consanguinity between 4th degree relatives and that the SLE could be having higher heritable potential than estimated so far. Marriage between 5th degree relatives does not seem to have the potential to increase the risk of familial SLE.</p><p>In our study, age of onset was similar in patients with sporadic and familial SLE (21.6 &#177; 5 years and 22.1 &#177; 5.95 years; <xref ref-type="table" rid="table4">Table 4</xref>), which is in accordance with the results of some other studies [<xref ref-type="bibr" rid="scirp.61778-ref15">15</xref>] . Clinical features of familial and sporadic SLE, including organ involvement, ICU admission rate, and ward admission rate showed similar percentages (<xref ref-type="table" rid="table4">Table 4</xref>). Similar clinical presentation of familial and sporadic form was confirmed by other studies, but they stressed that it varies greatly between different races [<xref ref-type="bibr" rid="scirp.61778-ref16">16</xref>] [<xref ref-type="bibr" rid="scirp.61778-ref17">17</xref>] . As our study included only patients of Saudi nationality, our results are in accordance with the results of other studies.</p><p>The result showed high prevalence of familial lupus among Saudi patients. However, the limited number of patients in both groups may be the factor where consanguinity and clinical characteristics comparisons were not entirely representative. Again, using the social media to collect patients may have some bias for sample collection although it may cover more geographic area over the country.</p></sec><sec id="s6"><title>6. Conclusion</title><p>In summary, our results show that a high percentage of familial lupus in Saudi patients may be a consequence of high consanguinity rate in Saudi Arabia. This study confirms findings of other studies in terms of similar clinical presentation and age of onset in patients with familiar and sporadic form of SLE. More research is required in order to estimate the actual inheritance pattern of familial SLE, as well as involvement of genetic and environmental factors.</p></sec><sec id="s7"><title>Cite this paper</title><p>Jamal AbdullahAlbishri,Samar SaadAlshehri,Alwalaa MohammedAltowairqi,Reem MagboulAljuaid, (2015) Familial Lupus and Clinical Characteristics in Saudi Arabia. International Journal of Clinical Medicine,06,899-905. doi: 10.4236/ijcm.2015.612117</p></sec><sec id="s8"><title>NOTES</title></sec></body><back><ref-list><title>References</title><ref id="scirp.61778-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Danchenko, N., Satia J, A. and Anthony, M.S. (2006) Epidemiology of Systemic Lupus Erythematosus: A Comparison of Worldwide Disease Burden. Lupus, 15, 308-318. http://dx.doi.org/10.1191/0961203306lu2305xx</mixed-citation></ref><ref id="scirp.61778-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Al-Arfaj, A.S., Al-Balla, S.R., Al-Dalaan, A.N., Al-Saleh, S.S., Bahabri, S.A., Mousa, M.M., et al. (2002) Prevalence of Systemic Lupus Erythematosus in Central Saudi Arabia. Saudi Medical Journal, 23, 87-89.</mixed-citation></ref><ref id="scirp.61778-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Alballa, S.R. (1995) Systemic Lupus Erythematosus in Saudi Patients. Clinical Rheumatology, 14, 342-346. http://dx.doi.org/10.1007/BF02208351</mixed-citation></ref><ref id="scirp.61778-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Al-Nasser, A.A., Aboul-Enein, M.-S. and Al-Aska, A.K. (1988) Systemic Lupus Erythematosus in Riyadh, Saudi Arabia. Journal of the Royal Society of Health, 108, 90-96.</mixed-citation></ref><ref id="scirp.61778-ref5"><label>5</label><mixed-citation publication-type="journal" xlink:type="simple"><name name-style="western"><surname>Criswell</surname><given-names> L.A. </given-names></name>,<etal>et al</etal>. (<year>2008</year>)<article-title>The Genetic Contribution to Systemic Lupus Erythematosus</article-title><source> Bulletin of the NYU Hospital for Joint Diseases</source><volume> 66</volume>,<fpage> 176</fpage>-<lpage>183</lpage>.<pub-id pub-id-type="doi"></pub-id></mixed-citation></ref><ref id="scirp.61778-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Priori, R., Medda, E., Conti, F., Cassara, E.A., Danieli, M.G., Gerli, R., et al. (2003) Familial Autoimmunity as a Risk Factor for Systemic Lupus Erythematosus and Vice Versa: A Case-Control Study. Lupus, 12, 735-740. http://dx.doi.org/10.1191/0961203303lu457oa</mixed-citation></ref><ref id="scirp.61778-ref7"><label>7</label><mixed-citation publication-type="book" xlink:type="simple">Duarte, C., Couto, M., Ines, L. and Liang, M.H. (2011) Chapter 36—Epidemiology of Systemic Lupus Erythematosus. In: Lahita, R.G., Ed., Systemic Lupus Erythematosus, 5th Edition, Academic Press, San Diego, 673-696. http://dx.doi.org/10.1016/B978-0-12-374994-9.10036-1</mixed-citation></ref><ref id="scirp.61778-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">(1992) Saudi Arabia [Electronic Resource]: A Country Study. Federal Research Division, Washington DC.</mixed-citation></ref><ref id="scirp.61778-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">El-Hazmi, M.A., Al-Swailem, A.R., Warsy, A.S., Al-Swailem, A.M., Sulaimani, R. and Al-Meshari, A.A. (1995) Consanguinity among the Saudi Arabian Population. Journal of Medical Genetics, 32, 623-626. http://dx.doi.org/10.1136/jmg.32.8.623</mixed-citation></ref><ref id="scirp.61778-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">(NHS) (2015) NGaGEC. First-Degree Relative 2015.http://www.geneticseducation.nhs.uk/genetic-glossary/181-first-degree-relative</mixed-citation></ref><ref id="scirp.61778-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">El-Mouzan, M.I., Al-Salloum, A.A., Al-Herbish, A.S., Qurachi, M.M. and Al-Omar, A.A. (2007) Regional Variations in the Prevalence of Consanguinity in Saudi Arabia. Saudi Medical Journal, 28, 1881-1884.</mixed-citation></ref><ref id="scirp.61778-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Qari, A., Al-Mayouf, S. and Al-Owain, M. (2009) Mode of Inheritance in Systemic Lupus Erythematosus in Saudi Multiplex Families. Genetic Counseling, 20, 215-223.</mixed-citation></ref><ref id="scirp.61778-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Eroglu, G.E. and Kohler, P.F. (2002) Familial Systemic Lupus Erythematosus: The Role of Genetic and Environmental Factors. Annals of the Rheumatic Diseases, 61, 29-31. http://dx.doi.org/10.1136/ard.61.1.29</mixed-citation></ref><ref id="scirp.61778-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Abutiban, F., Mokkaddam, K., Ameen, E., Moussa, M. and Alsaeid, K. (2009) Comparison between Familial and Sporadic Systemic Lupus Erythematosus in Kuwaiti Patients. Lupus, 18, 86-91.http://dx.doi.org/10.1177/0961203308094228</mixed-citation></ref><ref id="scirp.61778-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Koskenmies, S., Widen, E., Kere, J. and Julkunen, H. (2001) Familial Systemic Lupus Erythematosus in Finland. The Journal of Rheumatology, 28, 758-760.</mixed-citation></ref><ref id="scirp.61778-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Sestak, A.L., Nath, S.K., Kelly, J.A., Bruner, G.R., James, J.A. and Harley, J.B. (2008) Patients with Familial and Sporadic Onset SLE Have Similar Clinical Profiles But Vary Profoundly by Race. Lupus, 17, 1004-1009.http://dx.doi.org/10.1177/0961203308091969</mixed-citation></ref><ref id="scirp.61778-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Abid, N., Khan, A.S. and Al Otaibi, F.H. (2013) Systemic Lupus Erythematosus (SLE) in the Eastern Region of Saudi Arabia. A Comparative Study. Lupus, 22, 1529-1533. http://dx.doi.org/10.1177/0961203313500548</mixed-citation></ref></ref-list></back></article>